Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques

Vaccine

Volumn 29, Issue 17, 2011, Pages 3124-3137

  Marthas, Marta L ^a   Van Rompay, Koen K A ^a   Abbott, Zachary ^a   Earl, Patricia ^b   Buonocore Buzzelli, Linda ^c   Moss, Bernard ^b   Rose, Nina F ^c   Rose, John K ^c   Kozlowski, Pamela A ^d   Abel, Kristina ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Mucosal immunity; Pediatric HIV vaccine; SIV

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A; MODIFIED VACCINIA ANKARA VIRUS VECTOR; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS VECTOR; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE SEQUENCE; DRUG EFFICACY; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; MACACA; MALE; MEMORY T LYMPHOCYTE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIREMIA; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, VIRAL; BLOOD; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DRUG CARRIERS; FEMALE; GENETIC VECTORS; IMMUNOGLOBULIN A; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MALE; SAIDS VACCINES; SALIVA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T-LYMPHOCYTES, REGULATORY; VACCINATION; VACCINIA VIRUS; VESICULOVIRUS;

EID: 79954591698     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.051     Document Type: Article

References (43)

1. Mofenson L.M. Antiretroviral drugs to prevent breastfeeding HIV transmission. Antivir Ther 2010, 15(4):537-553.
2. Mofenson L.M. Protecting the next generation - eliminating perinatal HIV-1 infection. N Engl J Med 2010, 362(June (24)):2316-2318.
3. Zolfo M., De Weggheleire A., Schouten E., Lynen L. Time for " test and treat" in prevention of mother-to-child transmission programs in low- and middle-income countries. J Acquir Immune Defic Syndr 2010, 55(November (3)):287-289.
4. Marazzi M.C., Liotta G., Nielsen-Saines K., Haswell J., Magid N.A., Buonomo E., et al. Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life. AIDS 2010, 24(November (18)):2819-2826.
5. van der Horst C., Chasela C., Ahmed Y., Hoffman I., Hosseinipour M., Knight R., et al. Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi. Contemp Clin Trials 2009, 30(January (1)):24-33.
6. Abel K. The rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategies. Curr HIV Res 2009, 7(January (1)):2-11.
7. Luzuriaga K. Mother-to-child transmission of HIV: a global perspective. Curr Infect Dis Rep 2007, 9(November (6)):511-517.
8. Luzuriaga K., Newell M.L., Dabis F., Excler J.L., Sullivan J.L. Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities. Lancet 2006, 368(August (9534)):511-521.
9. Marthas M.L., Miller C.J. Developing a neonatal HIV vaccine: insights from macaque models of pediatric HIV/AIDS. Curr Opin HIV AIDS 2007, 2(September (5)):367-374.
10. Safrit J.T. HIV vaccines in infants and children: past trials, present plans and future perspectives. Curr Mol Med 2003, 3(May (3)):303-312.
11. Abel K., Pahar B., Van Rompay K.K., Fritts L., Sin C., Schmidt K., et al. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J Virol 2006, 80(July (13)):6357-6367.
12. Van Rompay K.K., Abel K., Lawson J.R., Singh R.P., Schmidt K.A., Evans T., et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005, 38(February (2)):124-134.
13. Van Rompay K., Abel K., Earl P., Kozlowski P.A., Easlick J., Moore J.P., et al. Immunogenicity of viral vector, prime -boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. Vaccine 2010, 28(6):1481-1492.
14. Van Rompay K.K., Schmidt K.A., Lawson J.R., Singh R., Bischofberger N., Marthas M.L. Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus. J Infect Dis 2002, 186(November (10)):1508-1513.
15. Earl P.L., Wyatt L.S., Montefiori D.C., Bilska M., Woodward R., Markham P.D., et al. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 2002, 294(March (2)):270-281.
16. Kozlowski P.A., Lynch R.M., Patterson R.R., Cu-Uvin S., Flanigan T.P., Neutra M.R. Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J Acquir Immune Defic Syndr 2000, 24(August (4)):297-309.
17. Manrique M., Kozlowski P.A., Wang S.W., Wilson R.L., Micewicz E., Montefiori D.C., et al. vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. Mucosal Immunol 2009, 2(November (6)):536-550.
18. Cline A.N., Bess J.W., Piatak M., Lifson J.D. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 2005, 34(October (5-6)):303-312.
19. Sun Y., Permar S.R., Buzby A.P., Letvin N.L. Memory CD4+ T-lymphocyte loss and dysfunction during primary simian immunodeficiency virus infection. J Virol 2007, 81(August (15)):8009-8015.
20. Erkeller-Yuksel F.M., Deneys V., Yuksel B., Hannet I., Hulstaert F., Hamilton C., et al. Age-related changes in human blood lymphocyte subpopulations. J Pediatr 1992, 120(February (2 Pt 1)):216-222.
21. Shahabuddin S., Al-Ayed I., Gad El-Rab M.O., Qureshi M.I. Age-related changes in blood lymphocyte subsets of Saudi Arabian healthy children. Clin Diagn Lab Immunol 1998, 5(September (5)):632-635.
22. Shahabuddin S., al Ayed I.H., el-Rad M.O., Qureshi M.I. Lymphocyte subset reference ranges in healthy Saudi Arabian children. Pediatr Allergy Immunol 1998, 9(February (1)):44-48.
23. Shearer W.T., Rosenblatt H.M., Gelman R.S., Oyomopito R., Plaeger S., Stiehm E.R., et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003, 112(November (5)):973-980.
24. Wang X., Rasmussen T., Pahar B., Poonia B., Alvarez X., Lackner A.A., et al. Massive infection and loss of CD4+ T cells occurs in the intestinal tract of neonatal rhesus macaques in acute SIV infection. Blood 2007, 109(February (3)):1174-1181.
25. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(December (23)):2209-2220.
26. Clarke D.K., Nasar F., Lee M., Johnson J.E., Wright K., Calderon P., et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol 2007, 81(February (4)):2056-2064.
27. Egan M.A., Chong S.Y., Rose N.F., Megati S., Lopez K.J., Schadeck E.B., et al. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 2004, 20(September (9)):989-1004.
28. Marthas M.L., Lu D., Penedo M.C., Hendrickx A.G., Miller C.J. Titration of an SIVmac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: transmission efficiency, viral loads, and antibody responses. AIDS Res Hum Retroviruses 2001, 17(October (15)):1455-1466.
29. Alpert M.D., Rahmberg A.R., Neidermyer W., Ng S.K., Carville A., Camp J.V., et al. Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge. J Virol 2010, 84(October (20)):10748-10764.
30. Feng T., Elson C.O. Adaptive immunity in the host-microbiota dialog. Mucosal Immunol 2011, 4(January (1)):15-21.
31. Kelleher A.D., Zaunders J.J. Decimated or missing in action: CD4+ T cells as targets and effectors in the pathogenesis of primary HIV infection. Curr HIV/AIDS Rep 2006, 3(February (1)):5-12.
32. Mattapallil J.J., Letvin N.L., Roederer M. T-cell dynamics during acute SIV infection. AIDS 2004, 18(January (1)):13-23.
33. Verhoeven D., Sankaran S., Silvey M., Dandekar S. Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells. J Virol 2008, 82(April (8)):4016-4027.
34. Zaunders J.J., Dyer W.B., Munier M.L., Ip S., Liu J., Amyes E., et al. CD127+CCR5+CD38+++ CD4+ Th1 effector cells are an early component of the primary immune response to vaccinia virus and precede development of interleukin-2+ memory CD4+ T cells. J Virol 2006, 80(October (20)):10151-10161.
35. Zaunders J.J., Ip S., Munier M.L., Kaufmann D.E., Suzuki K., Brereton C., et al. Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J Virol 2006, 80(October (20)):10162-10172.
36. Wang X., Xu H., Pahar B., Alvarez X., Green L.C., Dufour J., et al. Simian immunodeficiency virus selectively infects proliferating CD4+ T cells in neonatal rhesus macaques. Blood 2010, 116(November (20)):4168-4174.
37. Chase A.J., Sedaghat A.R., German J.R., Gama L., Zink M.C., Clements J.E., et al. Severe depletion of CD4+ CD25+ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection. J Virol 2007, 81(December (23)):12748-12757.
38. Qin S., Sui Y., Soloff A.C., Junecko B.A., Kirschner D.E., Murphey-Corb M.A., et al. Chemokine and cytokine mediated loss of regulatory T cells in lymph nodes during pathogenic simian immunodeficiency virus infection. J Immunol 2008, 180(April (8)):5530-5536.
39. Dunham R.M., Cervasi B., Brenchley J.M., Albrecht H., Weintrob A., Sumpter B., et al. CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection. J Immunol 2008, 180(April (8)):5582-5592.
40. Van Rompay K.K., Berardi C.J., Dillard-Telm S., Tarara R.P., Canfield D.R., Valverde C.R., et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 1998, 177(May (5)):1247-1259.
41. Van Rompay K.K., Greenier J.L., Cole K.S., Earl P., Moss B., Steckbeck J.D., et al. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol 2003, 77(January (1)):179-190.
42. Greenier J.L., Miller C.J., Lu D., Dailey P.J., Lu F.X., Kunstman K.J., et al. Route of simian immunodeficiency virus inoculation determines the complexity but not the identity of viral variant populations that infect rhesus macaques. J Virol 2001, 75(April (8)):3753-3765.
43. Ma Z-M, Keele BF, Qureshi H, Stone M, DeSilva V, Fritts L, et al. SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma, J Virol 2011, submitted.